Plain-English translation of NCT05904665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After colorectal cancer surgery, patients need careful monitoring to catch any recurrence early. This trial tests a new blood test called circulating tumor DNA (ctDNA) methylation detection—a more sensitive way to spot cancer cells in your bloodstream. The study compares this new blood test combined with routine follow-up care to routine follow-up alone, over 2 years.
Current methods to monitor for colorectal cancer recurrence, like blood markers and CT scans, are not very reliable or sensitive. The new blood test may detect cancer recurrence much earlier than existing methods, giving doctors a better chance to treat it before it spreads.
You likely qualify if…
You likely don't qualify if…
You will have blood tests drawn before surgery, within one month after surgery, and every three months for 2 years. If the blood test suggests cancer may have returned, you'll get additional imaging scans (CT scans). You'll also receive standard follow-up care as usual. The study team will track your health and any signs of recurrence throughout the 2 years.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China